{"filing":{"accession_number":"0001104659-26-084086","cik":"0001819411","ticker":"GANX","company_name":"Gain Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"tm2620618d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926084086/tm2620618d1_8k.htm"},"events":[{"id":18292,"run_id":16440,"accession_number":"0001104659-26-084086","anchor_item_number":"8.01","event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.75,"summary":"The disclosure states that current cash and cash equivalents are \"anticipated to fund the Company's operations into the second quarter of 2027, based on current operating plans.\" This language signals a limited cash runway of approximately 9 months from the filing date, which raises substantial doubt about the registrant's ability to continue as a going concern beyond Q2 2027 without additional financing. While the filing does not use the explicit phrase \"going concern,\" the quantified cash depletion timeline is a material indicator of liquidity stress typical of going-concern disclosures.","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17057,"accession_number":"0001104659-26-084086","item_number":"8.01","item_title":"Other Events.","event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.75,"reasoning":"The disclosure states that current cash and cash equivalents are \"anticipated to fund the Company's operations into the second quarter of 2027, based on current operating plans.\" This language signals a limited cash runway of approximately 9 months from the filing date, which raises substantial doubt about the registrant's ability to continue as a going concern beyond Q2 2027 without additional financing. While the filing does not use the explicit phrase \"going concern,\" the quantified cash depletion timeline is a material indicator of liquidity stress typical of going-concern disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:53:36.137551+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17057,"accession_number":"0001104659-26-084086","item_number":"8.01","item_title":"Other Events.","event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.75,"reasoning":"The disclosure states that current cash and cash equivalents are \"anticipated to fund the Company's operations into the second quarter of 2027, based on current operating plans.\" This language signals a limited cash runway of approximately 9 months from the filing date, which raises substantial doubt about the registrant's ability to continue as a going concern beyond Q2 2027 without additional financing. While the filing does not use the explicit phrase \"going concern,\" the quantified cash depletion timeline is a material indicator of liquidity stress typical of going-concern disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:53:36.137551+00:00","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-07-16"}]}